ReviewViruses2026
Molecular Mechanisms of Zika Virus Entry into Host Cells.
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The World Health Organization classifies mosquito-borne viruses as a major global public health threat with pandemic risk and urges all nations to strengthen pandemic preparedness. As a representative mosquito-borne flavivirus, ZIKV bears prominent pandemic capacity. Its distinctive neurotropic property and capability of vertical transmission create unique pathogenic hazards and transmission risks. Owing to the absence of approved vaccines and targeted antiviral therapeutics, the prevention and management of ZIKV outbreaks remain extremely challenging. Viral entry into host cells marks the very first step of productive ZIKV infection, and mechanistic investigations into this entry process lay an essential theoretical foundation for developing small-molecule agents that block ZIKV cellular entry. This review summarizes recent advances concerning ZIKV host receptor usage, membrane fusion cascades, and entry-targeted inhibitor development; systematically discusses existing inconsistencies and core controversies in cell type-dependent entry pathways, functionally redundant host receptor usage, especially the disputed AXL receptor, and unresolved molecular details of membrane fusion resulting from diverse experimental models and technical limitations; and proposes targeted future research directions to resolve these bottlenecks and clarify the context-dependent ZIKV entry mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.